Cargando…
Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study
PURPOSE: Reactive oxygen species modulator 1 (ROMO1) is a novel protein regulating intracellular reactive oxygen species production. Although increased ROMO1 expression has been associated with poor clinical outcomes in several human malignancies, the clinical implication of this protein in a radiot...
Autores principales: | Kong, Moonkyoo, Sung, Ji-Youn, Lee, Seung Hyeun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790331/ https://www.ncbi.nlm.nih.gov/pubmed/31632076 http://dx.doi.org/10.2147/OTT.S217514 |
Ejemplares similares
-
Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study
por: Kong, Moonkyoo, et al.
Publicado: (2020) -
Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
por: Kong, Moonkyoo, et al.
Publicado: (2021) -
Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage III non-small cell lung cancer
por: Kong, Moonkyoo, et al.
Publicado: (2016) -
Chronic hyperglycemia is an adverse prognostic factor for locoregional recurrence‐free survival in small cell lung cancer patients treated with radical radiotherapy
por: Kong, Moonkyoo, et al.
Publicado: (2022) -
Comparative survival analysis of preoperative and postoperative radiotherapy in stage II-III rectal cancer on the basis of long-term population data
por: Lim, Yu Jin, et al.
Publicado: (2018)